Zai Lab Limited (ZLAB) Earnings Call Transcripts
Zai Lab Limited's Latest Earnings Call - April 20, 2026
In the first quarter of 2026, Zai Lab Limited reported significant advancements in its clinical pipeline, particularly for Zoci (zocilurtatug pelitecan) in treating small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinomas (EP-NEC). The company highlighted a 54% overall intracranial response rate for Zoci, exceeding standard care benchmarks of 20-30%. Management maintained guidance on ongoing Phase III trials, anticipating interim results by mid-2027, which could lead to accelerated approval in 2028. Revenue and earnings details were not disclosed, but the focus on Zoci's promising data could drive stock performance in the near term.
Reported metrics
| Metric | Value |
|---|---|
| Overall Intracranial Response Rate | 54% (beat) |
| Response Rate at 1.6 mg/kg Dose | 62% (beat) |
| Enrollment Completion for Phase III Study | 1H 2027 (inline) |
| Projected Accelerated Approval | 2028 (positive) |
| Overall Response Rate in EP-NEC | 38% (positive) |
| Safety Profile | Grade 3 or 4 events in 15% (positive) |
Guidance from management
Management maintained guidance on the ongoing Phase III study for Zoci, with expectations for interim results by mid-2027, which could lead to accelerated approval in 2028.
What management said
No, nothing else. I think the disruption of the blood-brain barrier is an excellent point. And also, this is a very aid antibody with very, very low nanomolar affinity. So binding to DLL3 is with very high affinity. So perhaps that is one differentiating factor that makes it possible to have such high activity.
What analysts pressed on
Analysts expressed concerns about the long-term durability of responses and the potential impact of prior treatments on Zoci's efficacy. There were questions regarding the comparative effectiveness of Zoci against existing therapies in the first-line setting.
Main topics on the call
- Intracranial Activity of Zoci — Zoci demonstrated a 54% overall intracranial response rate in patients with extensive stage SCLC, with a notable 62% response rate at the 1.6 mg/kg dosage. Dr. Paz-Ares stated, "the early data are really encouraging" com...
- Ongoing Clinical Trials — Zai Lab is advancing Zoci through multiple lines of therapy, with a Phase III study expected to complete enrollment in the first half of 2027. Dr. Amado mentioned, "we are executing against a comprehensive global develop...
- Collaboration with Amgen and Boehringer Ingelheim — Zai Lab announced collaborations to explore combination therapies with Zoci, aiming to enhance treatment efficacy in SCLC and EP-NEC. This strategy is expected to deepen and extend responses with minimal overlapping toxi...
- Safety Profile of Zoci — Zoci maintained a favorable safety profile, with most adverse events being low grade. Dr. Thummalapalli noted, "the safety profile is consistent with what we observed in small cell lung cancer".
Read the full Zai Lab Limited transcript (April 20, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Zai Lab Limited
Zai Lab Limited (ZLAB) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 51 calls on record spanning January 14, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 51 Zai Lab Limited earnings call transcripts on record, spanning January 14, 2020 to August 6, 2026. Based on this history, Zai Lab Limited reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ZLAB
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 51
- First call
- January 14, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly